Test for Dental Implant Failed

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Dental Implant Failed
Azithromycin - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study the effect of preoperative azithromycin on implant surgery outcomes. It is a double-masked, placebo-controlled, randomized clinical trial.

Treatment Effectiveness

Study Objectives

1 Primary · 22 Secondary · Reporting Duration: 1 week, 4 months, 1 year

Year 1
modified plaque index
postoperative morbidities A
postoperative morbidities B
postoperative morbidities C
postoperative morbidities D
4 months, 1 year
bleeding index
peri-implant crestal bone change
postoperative morbidities E
postoperative morbidities F
postoperative morbidities G
postoperative morbidities H
postoperative morbidities I
postoperative morbidities J
probing depth
suppuration
survival rate
daily for 1 week
interferences with daily activities
postoperative analgesics taken
immediately postoperatively
duration of surgery (minutes)
insertion torque (Ncm)
surgical parameter
preop and 1 week
anxiety
Week 1
pain severity

Trial Safety

Trial Design

2 Treatment Groups

Test
1 of 2
control
1 of 2
Active Control
Non-Treatment Group

50 Total Participants · 2 Treatment Groups

Primary Treatment: Test · Has Placebo Group · Phase 1

Test
Drug
ActiveComparator Group · 1 Intervention: Azithromycin · Intervention Types: Drug
control
Drug
PlaceboComparator Group · 1 Intervention: Placebo oral tablet · Intervention Types: Drug

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 week, 4 months, 1 year

Who is running the clinical trial?

Centre de Recherche du Centre Hospitalier de l'Université de MontréalOTHER
49 Previous Clinical Trials
93,802 Total Patients Enrolled
Université de MontréalLead Sponsor
194 Previous Clinical Trials
92,666 Total Patients Enrolled
Robert Durand, DMD, MSPrincipal InvestigatorUniversité de Montréal
1 Previous Clinical Trials
42 Total Patients Enrolled
Intissar Abbaoui, DDSStudy DirectorUniversité de Montréal

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Subjects must be able and willing to provide written informed consent and comply with study procedures.
You have 1 or 2 implants restored with a crown or fixed bridge.
You have a partially edentulous alveolar ridge that is planned to be restored with no more than 2 implants.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 5th, 2021

Last Reviewed: October 3rd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References